J&J | JNJ - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 58.94B 4.03B 2025-12
Abbott USD 29.64B 19.74B 2026-03
Amgen USD 51.89B 1.88B 2026-03
AstraZeneca USD 25.96B 177M 2026-03
Baxter International USD 8.62B 852M 2026-03
Bayer EUR 30.68B 1.15B 2026-03
Becton, Dickinson and Co. USD 14.71B 2.21B 2026-03
Biogen USD 6.29B 1.7M 2026-03
Boston Scientific USD 11.01B 19M 2025-12
Bristol-Myers Squibb USD 42.15B 698M 2026-03
CONMED USD 834.23M 18.78M 2025-12
Cooper Companies USD 1.86B 17.7M 2026-03
Dexcom USD 1.3B 54.4M 2026-03
Edwards Lifesciences USD 600M 1.7M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Globus Medical USD 436K 9K 2025-12
Insulet USD 929.5M 1.3M 2026-03
Integra LifeSciences USD 1.83B 29.45M 2026-03
Intuitive Surgical USD 0 0 2025-03
J&J USD 37.53B 1.91B 2026-03
Medtronic USD 27.88B 255M 2025-12
Merck USD 46.67B 77M 2026-03
Merit Medical Systems USD 735.16M 1.12M 2026-03
Novartis USD 37.45B 7.86B 2026-03
Pfizer USD 60.57B 1.08B 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
Stryker USD 14.22B 635M 2026-03
Tandem Diabetes Care USD 601.77M 291.73M 2026-03
Teva Pharmaceutical Industries USD 14.02B 971M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Zimmer Biomet Holdings USD 6.3B 636.9M 2026-03
Zoetis USD 9.04B 3M 2026-03